Skip to main content

Advertisement

SpringerLink
Log in

Statin myopathy: Incidence, risk factors, and pathophysiology

  • Published:
Current Atherosclerosis Reports Aims and scope Submit manuscript

Abstract

3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) are generally well-tolerated lipid-lowering drugs. However, they are associated with myopathy, and incidence rates of muscle-related complaints predicted from clinical trials may underestimate rate of occurrence of these side effects in clinical practice. The development of a standardized system for description and documentation of statin-associated myopathy that includes the entire spectrum of muscle complaints would provide valuable data for researchers and clinicians seeking to better understand statin-induced muscle complaints. Among the risk factors for myopathy are polypharmacy, high-dose statin treatment, aging, and diabetes. The etiology of statin-induced myopathy is not well understood, but potential contributing mechanisms include decreases in mevalonate pathway products, mitochondrial dysfunction, alterations in gene expression related to apoptosis and protein degradation, and genetic predisposition.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Thompson PD, Clarkson P, Karas RH: Statin-associated myopathy. JAMA 2003, 289:1681–1690.

    Article  PubMed  CAS  Google Scholar 

  2. Jacobson TA: Statin safety: lessons from new drug applications for marketed statins. Am J Cardiol 2006, 97(8A):44C–51C.

    Article  PubMed  CAS  Google Scholar 

  3. Merck & Co: I: MECACOR (LOVASTATIN). In: Prescription Information. 2005.

  4. Kashani A, Phillips CO, Foody JM, et al.: Risks associated with statin therapy: a systematic overview of randomized clinical trials. Circulation 2006, 114:2788–2797.

    Article  PubMed  CAS  Google Scholar 

  5. Thavendiranathan P, Bagai A, Brookhart MA, Choudhry NK: Primary prevention of cardiovascular diseases with statin therapy: a meta-analysis of randomized controlled trials. Arch Intern Med 2006, 166:2307–2313.

    Article  PubMed  CAS  Google Scholar 

  6. Maggini M, Raschetti R, Traversa G, et al.: The cerivastatin withdrawal crisis: a “post-mortem” analysis. Health Policy (Amsterdam) 2004, 69:151–157.

    Google Scholar 

  7. Pasternak RC, Smith SC Jr, Bairey-Merz CN, et al.: ACC/AHA/NHLBI clinical advisory on the use and safety of statins. J Am Coll Cardiol 2002, 40:567–572.

    Article  PubMed  Google Scholar 

  8. Yilmaz MB, Pinar M, Naharci I, et al.: Being well-informed about statin is associated with continuous adherence and reaching targets. Cardiovasc Drugs Ther 2005, 19:437–440.

    Article  PubMed  Google Scholar 

  9. Hansen KE, Hildebrand JP, Ferguson EE, Stein JH: Outcomes in 45 patients with statin-associated myopathy. Arch Intern Med 2005, 165:2671–2676.

    Article  PubMed  Google Scholar 

  10. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002, 360:7–22.

  11. Sinzinger H, Wolfram R, Peskar BA: Muscular side effects of statins. J Cardiovasc Pharmacol 2002, 40:163–171.

    Article  PubMed  CAS  Google Scholar 

  12. Piercy MA, Sramek JJ, Kurtz NM, Cutler NR: Placebo response in anxiety disorders. Ann Pharmacother 1996, 30:1013–1019.

    PubMed  CAS  Google Scholar 

  13. Thompson PD, Clarkson PM, Rosenson RS: An assessment of statin safety by muscle experts. Am J Cardiol 2006, 97:69C–76C.

    Article  PubMed  CAS  Google Scholar 

  14. Jones JK: Spontaneous reports cannot serve as a basis for comparison of two drugs. Am J Cardiol 2003, 92:1141–1142.

    Article  PubMed  Google Scholar 

  15. de Lemos JA, Blazing MA, Wiviott SD, et al.: Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA 2004, 292:1307–1316.

    Article  PubMed  Google Scholar 

  16. Kent DH: When averages hide individual differences in clinical trials. Am Scientist 2007, 95:60–68.

    Google Scholar 

  17. Ballantyne CM, Corsini A, Davidson MH, et al.: Risk for myopathy with statin therapy in high-risk patients. Arch Inter Med 2003, 163:553–564.

    Article  CAS  Google Scholar 

  18. Talbert RL: Safety issues with statin therapy. J Am Pharm Assoc 2006, 46:479–488; quiz 488–490.

    Article  Google Scholar 

  19. Oh J, Ban M, Miskie B, et al.: Genetic determinants of statin intolerance. Lipids Health Dis 2007, 6:7.

    Article  PubMed  CAS  Google Scholar 

  20. Vermes A, Vermes I: Genetic polymorphisms in cytochrome P450 enzymes: effect on efficacy and tolerability of HMG-CoA reductase inhibitors. Am J Cardiovasc Drugs 2004, 4:247–255.

    Article  PubMed  CAS  Google Scholar 

  21. Baker SK: Molecular clues into the pathogenesis of statin-mediated muscle toxicity. Muscle Nerve 2005, 31:572–580.

    Article  PubMed  CAS  Google Scholar 

  22. Maitland-van der Zee AH, Boerwinkle E: Pharmacogenetics of response to statins: where do we stand? Curr Atheroscler Rep 2005, 7:204–208.

    Article  PubMed  CAS  Google Scholar 

  23. Ardern CI, Katzmarzyk PT, Janssen I, Church TS, Blair SN: Revised Adult Treatment Panel III Guidelines and Cardiovascular Disease Mortality in Men Attending a Preventive Medical Clinic. Circulation 2005, 112:1478–1485.

    Article  PubMed  Google Scholar 

  24. US Securities and Exchange Commission: Oldest Baby Boomers Turn 60!. Available at http://sec.gov/news/press/extra/seniors/agingboomers.htm. Accessed April 17, 2007.

  25. US Centers for Disease Control: National Diabetes Fact Sheet 2005. Available at http://www.cdc.gov/diabetes/pubs/estimates05. Accessed April 17, 2007.

  26. Sinzinger H, O’Grady J: Professional athletes suffering from familial hypercholesterolaemia rarely tolerate statin treatment because of muscular problems. Br J Clin Pharmacol 2004, 57:525–528.

    Article  PubMed  CAS  Google Scholar 

  27. Thompson PD, Zmuda JM, Domalik LJ, et al.: Lovastatin increases exercise-induced skeletal muscle injury. Metab Clin Exp 1997, 46:1206–1210.

    PubMed  CAS  Google Scholar 

  28. Omar MA, Wilson JP, Cox TS: Rhabdomyolysis and HMG-CoA reductase inhibitors. Ann Pharmacother 2001, 35:1096–1107.

    Article  PubMed  CAS  Google Scholar 

  29. Grundy SM, Cleeman JI, Merz CN, et al.: Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004, 110:227–239.

    Article  PubMed  Google Scholar 

  30. Bruckert E, Hayem G, Dejager S, et al.: Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients—the PRIMO study. Cardiovasc Drugs Ther 2005, 19:403–414.

    Article  PubMed  CAS  Google Scholar 

  31. Buse J: Statin treatment in diabetes mellitus. Clin Diabetes 2005, 21:168–172.

    Article  Google Scholar 

  32. Snow V, Aronson MD, Hornbake ER, et al.: Lipid control in the management of type 2 diabetes mellitus: a clinical practice guideline from the American College of Physicians. Ann Intern Med 2004, 140:644–649.

    PubMed  Google Scholar 

  33. Vijan S, Hayward RA: Pharmacologic lipid-lowering therapy in type 2 diabetes mellitus: background paper for the American College of Physicians. Ann Inter Med 2004, 140:650–658.

    CAS  Google Scholar 

  34. Graham DJ, Staffa JA, Shatin D, et al.: Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs. JAMA 2004, 292:2585–2590.

    Article  PubMed  CAS  Google Scholar 

  35. Jacobson TA: Overcoming ‘ageism’ bias in the treatment of hypercholesterolaemia: a review of safety issues with statins in the elderly. Drug Saf 2006, 29:421–448.

    Article  PubMed  CAS  Google Scholar 

  36. Ravnskov U: High cholesterol may protect against infections and atherosclerosis. QJM 2003, 96:927–934.

    Article  PubMed  CAS  Google Scholar 

  37. Guralnik JM, Alecxih L, Branch LG, Wiener JM: Medical and long-term care costs when older persons become more dependent. Am J Pub Health 2002, 92:1244–1245.

    Article  PubMed  Google Scholar 

  38. Desai MM, Zhang P, Hennessy CH: Surveillance for morbidity and mortality among older adults—United States, 1995–1996. MMWR CDC Surveill Summ 1999, 48:7–25.

    PubMed  CAS  Google Scholar 

  39. Ko DT, Mamdani M, Alter DA: Lipid-lowering therapy with statins in high-risk elderly patients: the treatment-risk paradox. JAMA 2004, 291:1864–1870.

    Article  PubMed  CAS  Google Scholar 

  40. Deedwania P, Stone PH, Bairey Merz CN, et al.: Effects of intensive versus moderate lipid-lowering therapy on myocardial ischemia in older patients with coronary heart disease: results of the Study Assessing Goals in the Elderly (SAGE). Circulation 2007, 115:700–707.

    Article  PubMed  CAS  Google Scholar 

  41. Clarkson PM, Nosaka K, Braun B: Muscle function after exercise-induced muscle damage and rapid adaptation. Med Sci Sports Exerc 1992, 24:512–520.

    PubMed  CAS  Google Scholar 

  42. Baker SK, Tarnopolsky MA: Statin myopathies: pathophysiologic and clinical perspectives. Clin Invest Med 2001, 24:258–272.

    PubMed  CAS  Google Scholar 

  43. Urso ML, Clarkson PM, Hittel D, et al.: Changes in ubiquitin proteasome pathway gene expression in skeletal muscle with exercise and statins. Arterioscler Thromb Vasc Biol 2005, 25:2560–2566.

    Article  PubMed  CAS  Google Scholar 

  44. Paiva H, Thelen KM, Van Coster R, et al.: High-dose statins and skeletal muscle metabolism in humans: a randomized, controlled trial. Clin Pharmacol Ther 2005, 78:60–68.

    Article  PubMed  CAS  Google Scholar 

  45. Phillips PS, Haas RH, Bannykh S, et al.: Statin-associated myopathy with normal creatine kinase levels. Ann Intern Med 2002, 137:581–585.

    PubMed  Google Scholar 

  46. Laaksonen R, Katajamaa M, Paiva H, et al.: A systems biology strategy reveals biological pathways and plasma biomarker candidates for potentially toxic statin-induced changes in muscle. PLoS ONE 2006, 1:e97.

    Article  PubMed  CAS  Google Scholar 

  47. Dricu A, Wang M, Hjertman M, et al.: Mevalonate-regulated mechanisms in cell growth control: role of dolichyl phosphate in expression of the insulin-like growth factor-1 receptor (IGF-1R) in comparison to Ras prenylation and expression of c-myc. Glycobiology 1997, 7:625–633.

    Article  PubMed  CAS  Google Scholar 

  48. Liao JK: Isoprenoids as mediators of the biological effects of statins. J Clin Invest 2002, 110:285–288.

    Article  PubMed  CAS  Google Scholar 

  49. Dirks AJ, Jones KM: Statin-induced apoptosis and skeletal myopathy. Am J Physiol 2006, 291:C1208–1212.

    Article  CAS  Google Scholar 

  50. Zhong WB, Wang CY, Chang TC, Lee WS: Lovastatin induces apoptosis of anaplastic thyroid cancer cells via inhibition of protein geranylgeranylation and de novo protein synthesis. Endocrinology 2003, 144:3852–3859.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Kinesiology, University of Massachusetts, Totman Building, 30 Eastman Lane, Amherst, MA, 01002, USA

    Priscilla M. Clarkson PhD

Authors
  1. Kimberly A. Sewright MS
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Priscilla M. Clarkson PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Paul D. Thompson MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Priscilla M. Clarkson PhD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Sewright, K.A., Clarkson, P.M. & Thompson, P.D. Statin myopathy: Incidence, risk factors, and pathophysiology. Curr Atheroscler Rep 9, 389–396 (2007). https://doi.org/10.1007/s11883-007-0050-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11883-007-0050-3

Keywords

Search

Navigation